Lung Cancer: Causes, Risk Factors, and Integrative Approaches to Prevention and Support

Introduction

Lung cancer is the leading cause of cancer-related death worldwide, accounting for more deaths annually than breast, colon, and prostate cancers combined. Approximately 238,000 new cases are diagnosed in the U.S. each year, with a 5-year survival rate of only 26% — largely because most cases are diagnosed at an advanced stage. Yet lung cancer is also one of the most preventable and metabolically targetable cancers, with a growing body of evidence supporting integrative strategies that address root causes, support immune function, and complement conventional treatment.

This article covers lung cancer types and molecular subtypes, root causes and risk factors, conventional treatment options, repurposed drug strategies, the Functional 13 Protocol adapted for lung cancer, subtype-specific compound guidance, and metabolic targeting approaches.

Types of Lung Cancer

1. Non-Small Cell Lung Cancer (NSCLC) — ~85% of cases

• Adenocarcinoma — the most common subtype; arises in peripheral lung tissue; most common in non-smokers and women; frequently harbors EGFR, ALK, ROS1, and KRAS mutations amenable to targeted therapy
• Squamous Cell Carcinoma — arises in central bronchial tissue; strongly associated with smoking; characterized by PD-L1 expression making it responsive to immunotherapy
• Large Cell Carcinoma — undifferentiated; aggressive; diagnosed by exclusion; poor prognosis

2. Small Cell Lung Cancer (SCLC) — ~15% of cases

Highly aggressive neuroendocrine tumor almost exclusively associated with smoking. Grows and metastasizes rapidly. Initially responsive to chemotherapy but almost universally develops resistance. Limited targeted therapy options; immunotherapy (atezolizumab) now approved in combination with chemotherapy.

3. Carcinoid Tumors (Neuroendocrine)

Rare, slow-growing neuroendocrine tumors. Typical carcinoids are low-grade; atypical carcinoids are more aggressive. Generally better prognosis than NSCLC or SCLC.

Molecular Subtypes & Targeted Mutations (NSCLC)

• EGFR-mutated (~15% of NSCLC in Western populations; ~50% in Asian populations) — targeted by osimertinib (Tagrisso), erlotinib, gefitinib
• ALK-rearranged (~5%) — targeted by alectinib, brigatinib, lorlatinib
• ROS1-rearranged (~2%) — targeted by crizotinib, entrectinib
• KRAS G12C-mutated (~13%) — targeted by sotorasib (Lumakras), adagrasib; historically undruggable
• PD-L1 high expressors — respond to pembrolizumab (Keytruda) monotherapy
• BRAF V600E (~2%) — targeted by dabrafenib + trametinib
• MET exon 14 skipping (~3%) — targeted by capmatinib, tepotinib

Molecular profiling (comprehensive genomic testing) is now standard of care for all advanced NSCLC patients and should be requested before initiating systemic therapy.

Root Causes & Risk Factors

1. Tobacco Smoke

Cigarette smoking remains the single largest risk factor, responsible for approximately 80–85% of lung cancer cases. Tobacco smoke contains over 70 known carcinogens — including polycyclic aromatic hydrocarbons (PAHs), nitrosamines, and benzene — which directly damage bronchial DNA and impair mucociliary clearance. Risk persists for decades after cessation but declines progressively.

2. Radon Gas Exposure

Radon — a naturally occurring radioactive gas that seeps from soil and rock — is the second leading cause of lung cancer, responsible for an estimated 21,000 deaths annually in the U.S. It accumulates in poorly ventilated basements and lower floors. Testing and mitigation are straightforward and highly effective. The EPA recommends mitigation when levels exceed 4 pCi/L.

3. Air Pollution & Environmental Carcinogens

Fine particulate matter (PM2.5), diesel exhaust, and industrial emissions significantly increase lung cancer risk. Indoor air pollutants — asbestos, secondhand smoke, formaldehyde, and cooking fumes from high-heat oils — are major contributors in non-smokers. A landmark 2023 study by Dr. Charles Swanton (Francis Crick Institute) demonstrated that PM2.5 promotes EGFR-mutant lung cancer in never-smokers by triggering inflammatory cascades in pre-existing mutant cells.

4. Occupational Exposures

Asbestos, arsenic, chromium, nickel, silica dust, and diesel exhaust are established occupational carcinogens. Workers in construction, mining, manufacturing, and transportation face elevated risk. Asbestos exposure combined with smoking is synergistically carcinogenic.

5. Chronic Inflammation & Immune Dysregulation

COPD, pulmonary fibrosis, and recurrent respiratory infections create pro-tumorigenic microenvironments. Elevated IL-6, TNF-α, and NF-κB activation promote cellular proliferation and suppress anti-tumor immune surveillance. Dr. Ilaria Bhatt (Harvard) has published extensively on inflammation-driven lung carcinogenesis in never-smokers.

6. Metabolic Dysfunction

Insulin resistance, hyperglycemia, and mitochondrial dysfunction favor the Warburg effect — aerobic glycolysis — in bronchial epithelial cells. Obesity and type 2 diabetes are associated with increased lung cancer risk and poorer outcomes. Dr. Thomas Seyfried's metabolic cancer framework is particularly applicable to SCLC and KRAS-mutant NSCLC, which are highly glycolytic.

7. Nutritional Deficiencies

Deficiencies in vitamin D, vitamin C, selenium, and carotenoids impair the body's ability to neutralize carcinogen-induced oxidative damage and maintain immune surveillance. The SELECT trial (Lippman et al., JAMA, 2009) highlighted the complexity of selenium supplementation timing and form in cancer prevention.

Symptoms

Early lung cancer is typically asymptomatic — which is why low-dose CT (LDCT) screening is critical for high-risk individuals. As disease progresses, symptoms may include:

• Persistent cough or change in chronic cough
• Hemoptysis (coughing up blood)
• Chest pain, particularly with deep breathing
• Shortness of breath or new-onset wheezing
• Hoarseness (recurrent laryngeal nerve involvement)
• Unexplained weight loss and fatigue
• Recurrent pneumonia or bronchitis
• Superior vena cava syndrome (facial swelling, arm swelling — indicates mediastinal involvement)
• Horner's syndrome (ptosis, miosis, anhidrosis — indicates Pancoast tumor)

Screening

The U.S. Preventive Services Task Force (USPSTF) recommends annual LDCT screening for adults aged 50–80 who have a 20 pack-year smoking history and currently smoke or quit within the past 15 years. The NLST trial demonstrated a 20% reduction in lung cancer mortality with LDCT vs. chest X-ray. Screening is underutilized — only ~6% of eligible Americans are screened annually.

Conventional Treatment Options

• Surgery — lobectomy or segmentectomy for early-stage NSCLC; VATS (video-assisted thoracoscopic surgery) is now standard for eligible patients
• Radiation — SBRT (stereotactic body radiation therapy) for early-stage inoperable disease; concurrent chemoradiation for locally advanced disease
• Chemotherapy — platinum-based doublets (carboplatin/paclitaxel, cisplatin/pemetrexed) remain backbone for advanced NSCLC without targetable mutations
• Targeted therapy — EGFR, ALK, ROS1, KRAS, BRAF, MET inhibitors (see molecular subtypes above)
• Immunotherapy — pembrolizumab (Keytruda), atezolizumab, nivolumab; PD-L1 expression and TMB guide selection
• Antibody-drug conjugates — patritumab deruxtecan (HER3-DXd) for EGFR-mutant NSCLC post-osimertinib

Evidence-Based Integrative Strategies

🥦 Dietary Approaches

• Cruciferous vegetables — sulforaphane activates NRF2, upregulating phase II detoxification enzymes; I3C and DIM modulate estrogen metabolism relevant in adenocarcinoma
• Carotenoids — lycopene, beta-carotene (from food, not high-dose supplements in smokers), lutein associated with reduced lung cancer risk in observational studies
• Omega-3 fatty acids — EPA and DHA reduce prostaglandin E2-driven inflammation; associated with improved outcomes in NSCLC patients on chemotherapy
• Green tea (EGCG) — inhibits EGFR signaling, VEGF-driven angiogenesis, and NF-κB; particularly relevant in EGFR-mutant adenocarcinoma
• Avoid high-heat refined seed oils — cooking fumes from oxidized polyunsaturated fats are a significant indoor carcinogen, particularly relevant in non-smoking Asian women with adenocarcinoma

🌿 Key Nutraceuticals

Repurposed Compounds & Emerging Investigational Approaches

A growing number of integrative oncologists are exploring repurposed compounds as adjunctive tools in lung cancer support. The following have generated significant interest based on preclinical data, mechanistic rationale, and clinical observations. This section is strictly educational and does not constitute medical advice. Always work with a qualified integrative physician.

🔬 Antiparasitic Agents

💊 Low Dose Naltrexone (LDN)

LDN (1.5–4.5mg at bedtime) transiently blocks opioid receptors, triggering rebound upregulation of the OGF–OGFr axis, which directly inhibits DNA synthesis in cancer cells. In lung cancer specifically:

• OGF receptor is expressed on NSCLC cell lines; OGF administration reduces tumor growth in xenograft models (Zagon et al., Cancer Letters, 2003)
• LDN modulates TLR4 signaling, reducing pro-tumor inflammatory cytokines (IL-6, TNF-α) that drive NSCLC progression
• Dr. Paul Marik's FLCCC cancer protocols include LDN as a standard adjunctive recommendation across cancer types
• Dr. Burt Berkson has documented LDN + alpha-lipoic acid combinations in cancer case reports
• Generally well-tolerated; must not be combined with opioid medications

🌿 CBD & Full Extract Cannabis Oil (FECO)

• CB1 and CB2 receptors are expressed on NSCLC cells; cannabinoid activation induces apoptosis and inhibits migration and invasion
• CBD has demonstrated anti-proliferative effects in NSCLC cell lines via inhibition of the EGF receptor pathway — directly relevant in EGFR-mutant adenocarcinoma (Ramer et al., Biochemical Pharmacology, 2010)
• THC has shown synergy with erlotinib (an EGFR inhibitor) in preclinical NSCLC models, enhancing apoptosis beyond either agent alone
• FECO (Full Extract Cannabis Oil / RSO) — full-spectrum formulations may produce synergistic entourage effects beyond isolated CBD
• Dr. Dustin Sulak (Healer.com) and Dr. Donald Abrams (UCSF Integrative Oncology) are among the leading clinicians documenting cannabinoid use in oncology support
• THC-containing formulations require legal consideration depending on jurisdiction

Cannabinoid use during active cancer treatment should be discussed with an oncologist, particularly regarding CYP450 interactions with targeted therapies like osimertinib and erlotinib.

🦠 Repurposed Antibiotics — Mitochondrial Targeting

• Doxycycline and azithromycin inhibit mitochondrial biogenesis in cancer stem cells, effectively starving them of energy production
• Dr. Michael Lisanti and Dr. Federica Sotgia (University of Salford) demonstrated doxycycline selectively targets cancer stem cells across multiple tumor types including NSCLC, with minimal effect on normal cells
• SCLC is particularly stem-cell-driven and may be especially vulnerable to mitochondrial targeting strategies
• A 2017 paper in Oncotarget (Lamb et al.) demonstrated doxycycline reduced cancer stem cell populations by up to 90% in certain models
• Dr. Marco Fiorillo has published extensively on the mitochondrial targeting hypothesis and antibiotic repurposing in oncology

Antibiotic use carries considerations around microbiome disruption and resistance; any use in a cancer-support context should be supervised by a physician familiar with this literature.

🧬 The Functional 13 Protocol: Adapted for Lung Cancer

The Functional 13 Protocol is an integrative support framework built around 13 compounds — repurposed antiparasitic agents, nutraceuticals, and immune modulators — each with preclinical or mechanistic relevance to cancer biology. Below is an educational overview adapted specifically for lung cancer biology, with subtype-specific notes where relevant.

🔗 How the Functional 13 Addresses Lung Cancer's Key Hallmarks

• Metabolic disruption — Fenbendazole, liposomal vitamin C, and green tea extract target glycolysis, OxPhos, and HIF-1α — the three primary energy pathways exploited by NSCLC and SCLC
• Immune activation — Turkey tail, lactoferrin, ivermectin, and CBD collectively support NK cell activity, macrophage repolarization, and immunogenic cell death — complementing checkpoint inhibitor immunotherapy
• EGFR/signaling pathway modulation — Green tea EGCG, curcumin, and CBD all interact with EGFR and downstream signaling — directly relevant in the most common NSCLC subtype
• Anti-metastatic support — Modified citrus pectin (galectin-3 inhibition) and CBD (anti-migration) address the lymphatic and hematogenous spread that makes lung cancer lethal
• Liver & detox support — Milk thistle and black seed oil protect hepatic function during chemotherapy and targeted therapy, many of which carry hepatotoxicity risk
• Synergistic amplification — Ivermectin's P-glycoprotein inhibition and piperine's bioavailability enhancement make each component more effective

The Functional 13 Protocol is presented here for educational purposes only. No treatment claims are made. Always consult a qualified integrative physician before beginning any multi-compound protocol alongside conventional cancer treatment.

💊 Additional Repurposed Pharmaceuticals — Lung Cancer-Specific Evidence

⚗️ Metabolic Targeting: Glutamine & the Lung Cancer Energy Landscape

NSCLC and SCLC cells — particularly KRAS-mutant and MYC-amplified subtypes — are highly dependent on glutamine as a secondary fuel source. Targeting glutamine metabolism is a logical complement to the glucose-disrupting compounds in the Functional 13 stack.

• Glutamine dependence — lung cancer cells use glutamine to fuel the TCA cycle, synthesize nucleotides for rapid DNA replication, and maintain redox balance via glutathione production; KRAS-mutant NSCLC upregulates glutamine uptake via ASCT2 transporter
• EGCG (green tea extract) — already in Functional 13; suppresses glutamine transporter ASCT2, reducing glutamine uptake into cancer cells
• Berberine — inhibits glutamine-driven mTORC1 activation; overlaps with metformin on AMPK pathway; consider as an add-on for KRAS-mutant NSCLC or SCLC specifically
• CBD — already in Functional 13; reduces glutamine synthetase activity in cancer cell lines
• Dietary strategy — reducing dietary glutamine (limiting processed meat, whey protein, MSG-heavy foods) may complement supplemental approaches; Dr. Thomas Seyfried advocates combining glucose and glutamine restriction as a metabolic cancer therapy framework
• DON (6-diazo-5-oxo-L-norleucine) — a glutamine antagonist with significant preclinical anti-tumor activity in NSCLC; being revisited in modified prodrug forms (DRP-104) to reduce GI toxicity; not yet widely available but worth monitoring

Glutamine targeting is most relevant in KRAS-mutant NSCLC and SCLC, where metabolic dependencies are most pronounced. Always discuss metabolic interventions with a physician familiar with oncology nutrition.

🎯 Subtype-Specific Integrative Considerations

Managing Treatment Side Effects Integratively

• Chemotherapy nausea — ginger root, acupuncture, B6
• Peripheral neuropathy — alpha-lipoic acid, B12 (methylcobalamin), acetyl-L-carnitine
• Fatigue — CoQ10, adaptogenic herbs (ashwagandha, rhodiola), gentle exercise
• Immunotherapy-related inflammation — omega-3s, curcumin, avoid high-dose antioxidants that may blunt immune activation
• EGFR inhibitor skin toxicity — topical aloe vera, zinc cream, vitamin E oil
• Pulmonary fibrosis risk (radiation/immunotherapy) — NAC, selenium, vitamin E tocotrienols
• Bone health (long-term targeted therapy) — vitamin D3 + K2, weight-bearing exercise, calcium

📋 Practitioner Resources & Further Reading:

• FLCCC Alliance Cancer Protocols: covid19criticalcare.com
• LDN Research Trust: ldnresearchtrust.org
• Dr. Dustin Sulak / Cannabinoid Medicine: healer.com
• Dr. Paolo Lissoni — Melatonin + chemotherapy RCTs: British Journal of Cancer, 1992–2003
• Dogra et al. — Fenbendazole anti-tumor activity: Scientific Reports, 2019
• Juarez et al. — Ivermectin anti-tumor review: Pharmacological Research, 2020
• Lisanti et al. — Doxycycline & cancer stem cells: Oncotarget, 2017
• Swanton et al. — PM2.5 & EGFR-mutant lung cancer: Nature, 2023

Conclusion

Lung cancer is a complex, molecularly diverse disease — but it is not beyond the reach of integrative medicine. Whether you are navigating EGFR-mutant adenocarcinoma, KRAS-mutant NSCLC, or aggressive SCLC, the combination of molecular-targeted conventional therapy with metabolic disruption, immune support, and the Functional 13 framework offers a multi-pronged approach grounded in mechanistic rationale and growing clinical evidence. The goal is not to replace standard care but to make the body a less hospitable environment for cancer while supporting quality of life throughout treatment.

This article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making changes to your health regimen.

References

• Siegel RL et al. (2023). Cancer Statistics. CA: A Cancer Journal for Clinicians.
• Dogra N et al. (2019). Fenbendazole acts as a moderate microtubule destabilizing agent and causes cancer cell death. Scientific Reports.
• Juarez M et al. (2020). Ivermectin as an antitumor agent. Pharmacological Research.
• Lissoni P et al. (1999). Randomized study of chemotherapy with or without melatonin in NSCLC. British Journal of Cancer.
• Skrott Z et al. (2017). Alcohol-abuse drug disulfiram targets cancer via p97 segregase adaptor NPL4. Nature.
• Tan BX et al. (2011). Metformin and lung cancer outcomes. Journal of Thoracic Oncology.
• Ramer R et al. (2010). Cannabidiol inhibits lung cancer cell invasion. Biochemical Pharmacology.
• Nangia-Makker P et al. (2002). Inhibition of human cancer cell growth by modified citrus pectin. JNCI.
• Standish LJ et al. (2008). Trametes versicolor mushroom immune therapy. Journal of the Society for Integrative Oncology.
• Khurana V et al. (2007). Statins reduce the risk of lung cancer. Journal of Clinical Oncology.
• Swanton C et al. (2023). Mechanism of action of air pollution in lung cancer in never-smokers. Nature.
• Padayatty SJ et al. (2004). Vitamin C pharmacokinetics. PNAS.
• Aggarwal BB et al. (2006). Curcumin suppresses NF-κB activation. Cancer Research.
• Lamb R et al. (2017). Antibiotics that target mitochondria effectively eradicate cancer stem cells. Oncotarget.